ArticleAnnals of nuclear medicine2025
Clinicopathologic and metabolic variables from
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Assessing Respiratory Motion Stability of NovelDiagnostics (Basel, Switzerland) · 2026Article
- The prognostic value ofAnnals of nuclear medicine · 2026Article
- A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances.Translational lung cancer research · 2025Review
- Histologic grade and STAS as key predictors of distant recurrence in resected early-stage lung adenocarcinoma: a single-center study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to analyze the clinicopathologic and metabolic parameters derived from staging MATERIAL AND
methodsRetrospective study included stage I-III NSCLC patients with a baseline
resultsOut of 173 patients, 104 experienced recurrences, with 66% presenting distant involvement and 56.7% exhibiting polymetastatic disease at initial recurrence. Patient age, pathologic lymphovascular invasion, and normalized SUVmax perimeter distance (nSPD) were considered as risk factors for early recurrence. Adenocarcinoma histology was identified as an independent variable for distant recurrence. Patient age, number of metastatic mediastinal lymph nodes at staging (nN), sphericity, normalized SUVpeak to centroid distance (nSCD), entropy, low gray-level run emphasis, and high gray-level run emphasis were independent variables for polymetastatic disease. Certain variables were correlated with organ-specific recurrence. Bone recurrence was related to nN and SUVmean. Brain recurrence was related to adenocarcinoma histology. Lung recurrence was associated with coefficient of variation and nSPD.
conclusionThe metabolic profile of lung primary tumors obtained from
Indexed as
Identifiers
39948296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.